罗氏制药：旗下创新药速福达正式在华获批扩龄至1岁及以上

Core Viewpoint - Roche Pharmaceuticals China announced the approval of its innovative antiviral treatment for influenza, Sufo Da® (Mabalosavir), by the National Medical Products Administration of China, expanding its indication for treating children aged 1 to under 5 years with uncomplicated type A and B influenza, including both previously healthy patients and those at high risk for influenza complications [1]. Group 1 - Roche's antiviral drug Sufo Da® received approval on March 3, 2026 [1]. - The drug is indicated for children aged 1 to under 5 years [1]. - The approval includes treatment for both uncomplicated type A and B influenza [1]. Group 2 - The drug is suitable for previously healthy children as well as those at high risk for influenza complications [1].